The Korea Journal of Herbology (대한본초학회지)

The Korea Association of Herbology (대한본초학회)
권호 표지
DOI QR코드

DOI QR Code

A review on the gut microbiome dysbiosis in diabetic patients and the improvement effects of traditional herbal medicine treatments

당뇨병 환자의 장내미생물 변화와 한의소재에 의한 개선효과 논문고찰

  • Hye-Min Yi (College of Korean Medicine, Dongshin University) ;
  • Sun-Young Hwang (College of Korean Medicine, Dongshin University) ;
  • Mee-Hyun Lee (College of Korean Medicine, Dongshin University)
  • 이혜민 (동신대학교 한의과대학 한의학과) ;
  • 황선영 (동신대학교 한의과대학 한의예과) ;
  • 이미현 (동신대학교 한의과대학 한의예과)
  • Received : 2024.09.09
  • Accepted : 2024.09.25
  • Published : 2024.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : Diabetes is a chronic disease that is rapidly increasing worldwide, and recent studies suggest that gut microbiome dysbiosis may be one of the main reasons for diabetes. Therefore, we have reviewed the relationship between diabetes and microbiome changes and their regulation by treatment of traditional herbal medicine. Methods : This review was prepared by querying in PubMed with the key words such as diabetes, microbiome and traditional herbal medicine. The search was conducted for research articles including both in vivo preclinical reports and clinical studies, up to July 22, 2024 within the past five years. Results : Gut microbiota dysbiosis is implicated in diabetes through major mechanisms, including increased endotoxin (LPS), decreased short-chain fatty acid (SCFA) production, reduced gut microbiota diversity, and impaired bile acid metabolism in mouse models and human cohorts. Traditional herbal medicines including berberine and bicalein and formulations such as Gegen Qinlian Decoction, Banxia Xiexin Decoction, and Huang-Lian-Jie-Du-Decoction improved diabetes by increasing the gut microbiota diversity and SCFA generation. Conclusion : Gut microbiota imbalance plays an important role in the onset and progression of diabetes especially type 2 diabetes which is improved by traditional herbal medicines promoting the growth of beneficial microbiome and suppressing pathogenic abundance. It may provide a promising prospect for more effective diabetes management and treatment strategies.

Keywords

Acknowledgement

본 논문은 과학기술정보통신부의 재원으로 한국연구재단의 지원 (No. 2022R1A5A2029546)과 연구개발특구진흥재단의 지원을 받아 수행됐습니다(No.2021-DD-UP-0380).

References

  1. 12. Older Adults: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1): S139-s47. https://doi.org/10.2337/dc19-S012
  2. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19-s40. https://doi.org/10.2337/dc23-S002
  3. Korean Diabetes Association. Diabetes Fact Sheet in Korea 2020
  4. Zhang S, Cai Y, Meng C, Ding X, Huang J, Luo X, et al. The role of the microbiome in diabetes mellitus. Diabetes Res Clin Pract. 2021;172:108645. https://doi.org/10.1016/j.diabres.2020.108645
  5. Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clement K. Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health-Pathophysiology and Therapeutic Strategies. Gastroenterology. 2021;160(2):573-99. https://doi.org/10.1053/j.gastro.2020.10.057
  6. Heintz-Buschart A, Wilmes P. Human Gut Microbiome: Function Matters. Trends Microbiol. 2018;26(7): 563-74. https://doi.org/10.1016/j.tim.2017.11.002
  7. Yang HT, Liu JK, Xiu WJ, Tian TT, Yang Y, Hou XG, et al. Gut Microbiome-Based Diagnostic Model to Predict Diabetes Mellitus. Bioengineered. 2021; 12(2):12521-34. https://doi.org/10.1080/21655979.2021.2009752
  8. Brar PC, Kohn B. Use of the microbiome in the management of children with type 2 diabetes mellitus. Curr Opin Pediatr. 2019;31(4):524-30. https://doi.org/10.1097/MOP.0000000000000781
  9. Ma Q, Li Y, Li P, Wang M, Wang J, Tang Z, et al. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora. Biomed Pharmacother. 2019;117:109138. https://doi.org/10.1016/j.biopha.2019.109138
  10. Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51: 102590. https://doi.org/10.1016/j.ebiom.2019.11.051
  11. Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem. 2019;63:101-8. https://doi.org/10.1016/j.jnutbio.2018.10.003
  12. Zhou Z, Sun B, Yu D, Zhu C. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus. Front Cell Infect Microbiol. 2022;12:834485. https://doi.org/10.3389/fcimb.2022.834485
  13. Candela M, Biagi E, Soverini M, Consolandi C, Quercia S, Severgnini M, et al. Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-Pi 2 diet. Br J Nutr. 2016; 116(1):80-93. https://doi.org/10.1017/S0007114516001045
  14. Salgaco MK, Oliveira LGS, Costa GN, Bianchi F, Sivieri K. Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus. Appl Microbiol Biotechnol. 2019;103(23-24):9229-38. https://doi.org/10.1007/s00253-019-10156-y
  15. Jia L, Huang S, Sun B, Shang Y, Zhu C. Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment. Front Endocrinol (Lausanne). 2023;14:1149256. https://doi.org/10.3389/fendo.2023.1149256
  16. Zhang R, Gao X, Bai H, Ning K. Traditional Chinese Medicine and Gut Microbiome: Their Respective and Concert Effects on Healthcare. Front Pharmacol. 2020;11:538. https://doi.org/10.3389/fphar.2020.00538
  17. Wang CH, Yen HR, Lu WL, Ho HH, Lin WY, Kuo YW, et al. Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus. Front Endocrinol (Lausanne). 2022;13:754401. https://doi.org/10.3389/fendo.2022.754401
  18. Wu Z, Zhang B, Chen F, Xia R, Zhu D, Chen B, et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study. Front Cell Infect Microbiol. 2022;12:1089991. https://doi.org/10.3389/fcimb.2022.1089991
  19. Sang TT, Guo CJ, Guo DD, Wang XY. [Effect of traditional Chinese medicine in inhibiting obesity and inflammatory diseases by regulating gut microbiota]. Zhongguo Zhong Yao Za Zhi. 2018; 43(16):3235-42.
  20. Lin L, Luo L, Zhong M, Xie T, Liu Y, Li H, et al. Gut microbiota: a new angle for traditional herbal medicine research. RSC Adv. 2019;9(30):17457-72. https://doi.org/10.1039/C9RA01838G
  21. Zheng Y, Ding Q, Wei Y, Gou X, Tian J, Li M, et al. Effect of traditional Chinese medicine on gut microbiota in adults with type 2 diabetes: A systematic review and meta-analysis. Phytomedicine. 2021;88:153455. https://doi.org/10.1016/j.phymed.2020.153455
  22. Yang S, Hao S, Wang Q, Lou Y, Jia L, Chen D. The interactions between traditional Chinese medicine and gut microbiota: Global research status and trends. Front Cell Infect Microbiol. 2022;12:1005730. https://doi.org/10.3389/fcimb.2022.1005730
  23. Li X, Wu D, Niu J, Sun Y, Wang Q, Yang B, et al. Intestinal Flora: A Pivotal Role in Investigation of Traditional Chinese Medicine. Am J Chin Med. 2021;49(2):237-68. https://doi.org/10.1142/S0192415X21500130
  24. Yang L, Yu S, Yang Y, Wu H, Zhang X, Lei Y, et al. Berberine improves liver injury induced glucose and lipid metabolic disorders via alleviating ER stress of hepatocytes and modulating gut microbiota in mice. Bioorg Med Chem. 2022;55:116598. https://doi.org/10.1016/j.bmc.2021.116598
  25. Zhang HY, Tian JX, Lian FM, Li M, Liu WK, Zhen Z, et al. Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota. Biomed Pharmacother. 2021; 133:110857. https://doi.org/10.1016/j.biopha.2020.110857
  26. Chu N, Chan JCN, Chow E. Pharmacomicrobiomics in Western Medicine and Traditional Chinese Medicine in Type 2 Diabetes. Front Endocrinol (Lausanne). 2022;13:857090. https://doi.org/10.3389/fendo.2022.857090
  27. Wang L, Zhang K, Zeng Y, Luo Y, Peng J, Zhang J, et al. Gut mycobiome and metabolic diseases: The known, the unknown, and the future. Pharmacol Res. 2023;193:106807. https://doi.org/10.1016/j.phrs.2023.106807
  28. Serrato RV. Lipopolysaccharides in diazotrophic bacteria. Front Cell Infect Microbiol. 2014;4:119. https://doi.org/10.3389/fcimb.2014.00119
  29. Saad MJ, Santos A, Prada PO. Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. Physiology (Bethesda). 2016;31(4):283-93. https://doi.org/10.1152/physiol.00041.2015
  30. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7): 1761-72. https://doi.org/10.2337/db06-1491
  31. Cipolletta C, Ryan KE, Hanna EV, Trimble ER. Activation of peripheral blood CD14+ monocytes occurs in diabetes. Diabetes. 2005;54(9):2779-86. https://doi.org/10.2337/diabetes.54.9.2779
  32. Fernandez-Real JM, Broch M, Richart C, Vendrell J, Lopez-Bermejo A, Ricart W. CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab. 2003;88(4):1780-4. https://doi.org/10.1210/jc.2002-020173
  33. Creely SJ, McTernan PG, Kusminski CM, Fisher f M, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292(3):E740-7. https://doi.org/10.1152/ajpendo.00302.2006
  34. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009;58(7):1509-17. https://doi.org/10.2337/db08-1637
  35. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54(9):2325-40. https://doi.org/10.1194/jlr.R036012
  36. Hu J, Lin S, Zheng B, Cheung PCK. Short-chain fatty acids in control of energy metabolism. Crit Rev Food Sci Nutr. 2018;58(8):1243-9. https://doi.org/10.1080/10408398.2016.1245650
  37. Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP, et al. Erratum: Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. The ISME Journal. 2014;8(6): 1323-25. https://doi.org/10.1038/ismej.2014.14
  38. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11(10): 577-91. https://doi.org/10.1038/nrendo.2015.128
  39. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490 (7418):55-60. https://doi.org/10.1038/nature11450
  40. He Y, Wu W, Zheng HM, Li P, McDonald D, Sheng HF, et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018;24(10):1532-5. https://doi.org/10.1038/s41591-018-0164-x
  41. Fan G, Cao F, Kuang T, Yi H, Zhao C, Wang L, et al. Alterations in the gut virome are associated with type 2 diabetes and diabetic nephropathy. Gut Microbes. 2023;15(1):2226925. https://doi.org/10.1080/19490976.2023.2226925
  42. Caricilli AM, Saad MJ. The role of gut microbiota on insulin resistance. Nutrients. 2013;5(3): 829-51. https://doi.org/10.3390/nu5030829
  43. Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):573-83. https://doi.org/10.1016/j.bpg.2014.07.004
  44. Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2): 225-35. https://doi.org/10.1016/j.cmet.2013.01.003
  45. Gonzalez FJ, Jiang C, Patterson AD. An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. Gastroenterology. 2016;151(5): 845-59. https://doi.org/10.1053/j.gastro.2016.08.057
  46. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014; 66(4):948-83. https://doi.org/10.1124/pr.113.008201
  47. Su M, Hu R, Tang T, Tang W, Huang C. Review of the correlation between Chinese medicine and intestinal microbiota on the efficacy of diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:1085092. https://doi.org/10.3389/fendo.2022.1085092
  48. He L, Yang FQ, Tang P, Gao TH, Yang CX, Tan L, et al. Regulation of the intestinal flora: A potential mechanism of natural medicines in the treatment of type 2 diabetes mellitus. Biomed Pharmacother. 2022;151:113091. https://doi.org/10.1016/j.biopha.2022.113091
  49. Chen Y, Wang M. New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes. Drug Des Devel Ther. 2021;15:4849-63. https://doi.org/10.2147/DDDT.S334325
  50. Chen S, Jiao Y, Han Y, Zhang J, Deng Y, Yu Z, et al. Edible traditional Chinese medicines improve type 2 diabetes by modulating gut microbiotal metabolites. Acta Diabetol. 2024;61(4):393-411. https://doi.org/10.1007/s00592-023-02217-6
  51. Jiang P, Di Z, Huang W, Xie L. Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications. Molecules. 2024;29(12):2747. https://doi.org/10.3390/molecules29122747
  52. Nie Q, Chen H, Hu J, Fan S, Nie S. Dietary compounds and traditional Chinese medicine ameliorate type 2 diabetes by modulating gut microbiota. Crit Rev Food Sci Nutr. 2019;59(6): 848-63. https://doi.org/10.1080/10408398.2018.1536646
  53. Zhang B, Yue R, Chen Y, Yang M, Huang X, Shui J, et al. Gut Microbiota, a Potential New Target for Chinese Herbal Medicines in Treating Diabetes Mellitus. Evid Based Complement Alternat Med. 2019;2019:2634898. https://doi.org/10.1155/2019/2634898
  54. Xu X, Yi H, Wu J, Kuang T, Zhang J, Li Q, et al. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomed Pharmacother. 2021;133:110984. https://doi.org/10.1016/j.biopha.2020.110984
  55. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012;7(8):e42529. https://doi.org/10.1371/journal.pone.0042529
  56. Xu X, Gao Z, Yang F, Yang Y, Chen L, Han L, et al. Antidiabetic Effects of Gegen Qinlian Decoction via the Gut Microbiota Are Attributable to Its Key Ingredient Berberine. Genomics Proteomics Bioinformatics. 2020;18(6):721-36. https://doi.org/10.1016/j.gpb.2019.09.007
  57. Chen M, Liao Z, Lu B, Wang M, Lin L, Zhang S, et al. Huang-Lian-Jie-Du-Decoction Ameliorates Hyperglycemia and Insulin Resistant in Association With Gut Microbiota Modulation. Front Microbiol. 2018;9:2380. https://doi.org/10.3389/fmicb.2018.02380
  58. Li SX, Guo Y. Gut microbiome: New perspectives for type 2 diabetes prevention and treatment. World J Clin Cases. 2023;11(31):7508-20. https://doi.org/ 10.12998/wjcc.v11.i31.7508
  59. Zhang B, Zhang X, Luo Z, Ren J, Yu X, Zhao H, et al. Microbiome and metabolome dysbiosis analysis in impaired glucose tolerance for the prediction of progression to diabetes mellitus. J Genet Genomics. 2024;51(1):75-86. https://doi.org/10.1016/j.jgg.2023.08.005
  60. Wu L, Gao Y, Su Y, Li J, Ren WC, Wang QH, et al. Probiotics with anti-type 2 diabetes mellitus properties: targets of polysaccharides from traditional Chinese medicine. Chin J Nat Med. 2022;20(9): 641-55. https://doi.org/10.1016/S1875-5364(22)60210-3
  61. Bao Y, Han X, Liu D, Tan Z, Deng Y. Gut microbiota: The key to the treatment of metabolic syndrome in traditional Chinese medicine - a case study of diabetes and nonalcoholic fatty liver disease. Front Immunol. 2022;13:1072376. https://doi.org/10.3389/fimmu.2022.1072376
  62. Cao H, Li C, Lei L, Wang X, Liu S, Liu Q, et al. Stachyose Improves the Effects of Berberine on Glucose Metabolism by Regulating Intestinal Microbiota and Short-Chain Fatty Acids in Spontaneous Type 2 Diabetic KKAy Mice. Front Pharmacol. 2020;11:578943. https://doi.org/10.3389/fphar.2020.578943